Article Figures & Data
Figures
- Figure 1.
Percentage of women at different ages of SLE onset for the overall 1000 Faces of Lupus cohort. Pediatric patients were excluded from analyses in this study.
Tables
Characteristic Early Onset Late Onset p N (%) 1367 (89.4) 161 (10.5) Female: male 8.83:1 7.47:1 0.5 Mean current age, yrs 41.64 ± 15.01 67.09 ± 8.42 Mean age at diagnosis, yrs 26.71 ± 11.36 57.90 ± 7.01 Mean disease duration, yrs 15.02 ± 10.48 9.3 ± 6.1 < 0.001 Caucasian (%) 760 (55.6) 120 (74.5) Asian (%) 249 (18.2) 5 (3.1) Black (%) 122 (8.9) 8 (5.0) Aboriginal (%) 71 (5.2) 5 (3.1) Latin/Hispanic (%) 22 (1.6) 2 (1.2) Jewish (%) 22 (1.6) 4 (2.5) Middle Eastern (%) 21 (1.5) 3 (1.9) - Table 2.
American College of Rheumatology criteria in early onset (< 50 yrs) vs late onset (≥ 50 yrs) SLE.
Early Onset Late Onset p Mean no. of ACR criteria met 5.98 ± 1.68 5.24 ± 1.44 0.007* Malar rash 813 (63.9) 72 (51.1) 0.002* Renal 613 (49.0) 33 (24.1) < 0.0001* Proteinuria 252 (80.3) 6 (37.5) < 0.0001* Neurological 130 (11.0) 6 (4.3) 0.01* Hematologic 1010 (77.9) 102 (68.0) 0.006* Immunologic 1128 (86.3) 118 (79.7) 0.006* Serositis 442 (36.1) 45 (32.1) 0.2 Pleuritis/pleural effusion 209 (76.8) 25 (73.5) 0.4 Seizures 46 (58.2) 1 (20.0) 0.1 Psychosis 29 (37.7) 1 (25.0) 0.5 Hemolytic anemia 111 (21.3) 8 (13.1) 0.09 Discoid rash 183 (15.4) 24 (17.9) 0.3 Photosensitivity 676 (54.2) 77 (55.0) 0.5 Arthritis 1041 (79.8) 125 (83.9) 0.1 Pericarditis 116 (43.8) 15 (45.4) 0.5 Cellular casts 152 (50.2) 11 (64.7) 0.2 Oral/nasal ulcerations 668 (53.4) 80 (58.0) 0.2 Lupus inhibitor/anticoagulant 52 (19.3) 8 (27.6) 0.2 False-positive VDRL 19 (6.9) 4 (13.3) 0.2 Thrombocytopenia 171 (31.8) 21 (33.9) 0.4 Lymphopenia 385 (69.7) 46 (70.8) 0.5 -
↵* Statistically significant. ACR: American College of Rheumatology; VDRL: Venereal Disease Research Laboratory.
-
Feature Early Onset, n (%) Late Onset, n (%) p Fever 183 (16.7) 10 (7.9) 0.009* Nephrotic syndrome 64 (6) 0 0.001* Alopecia 0 2 (2.5) 0.016* Arthralgias 582 (52.7) 75 (58.1) 0.3 Weight loss 188 (17.3) 25 (19.5) 0.5 Fatigue 559 (50.9) 70 (54.7) 0.5 Inflammatory arthritis 238 (21.7) 37 (29.1) 0.07 Deforming arthritis 80 (7.3) 12 (9.7) 0.4 Sicca complex 77 (13.3) 14 (16.5) 0.4 Fibromyalgia 155 (23.6) 18 (19.1) 0.4 Raynaud’s 434 (39.3) 61 (46.9) 0.1 Myositis 28 (2.6) 5 (4.0) 0.4 -
↵* Statistically significant.
-
Early Onset Late Onset p ANA-positive 1282 (97.0) 149 (96.8) 0.5 Anti-dsDNA-positive 514 (80.3) 64 (79.0) 0.4 Anti-Sm-positive 183 (29.9) 8 (10.5) < 0.0001* Anti-Ro/SSA antibodies 330 (33.5) 32 (27.8) 0.2 Anti-RNP antibodies 274 (28.8) 16 (13.8) < 0.0001* Anti-La/SSB antibodies 135 (14.4) 12 (10.6) 0.3 Anti-Jo1 antibodies 42 (4.5) 1 (0.9) 0.08 Anti-Scl70 antibodies 17 (1.9) 4 (3.5) 0.3 Antiphospholipid-positive 306 (50.0) 32 (42.7) 0.1 Anticardiolipin-positive 164 (58.0) 16 (55.2) 0.5 Low serum levels of complements (ever) 458 (41.8) 31 (25.0) < 0.0001* pANCA 29 (3.2) 5 (4.4) 0.4 cANCA 9 (1.0) 3 (2.7) 0.1 -
↵* Statistically significant. ANA: antinuclear antibody; dsDNA: double-stranded DNA; Sm: Smith; RNP: ribonucleoprotein; pANCA: perinuclear ANCA; cANCA: cytoplasmic ANCA.
-
Early Onset (%) Late Onset (%) p Charlson Index score (mean ± SD) 1.25 ± 0.75 1.43 ± 1.12 0.01* Congestive heart failure 13 (1.9) 8 (7.1) 0.02* Myocardial infarction 19 (2.8) 8 (7.1) 0.1 Peripheral vascular disease 8 (1.2) 0 0.2 Cerebrovascular disease 49 (7.2) 12 (10.6) 0.4 Dementia 1 (0.1) 1 (0.9) 0.4 Peptic ulcer disease 29 (4.3) 14 (12.5) 0.006* Moderate to severe renal disease 25 (3.7) 0 0.02* COPD 16 (2.4) 7 (6.2) 0.1 Mild liver disease 3 (0.4) 3 (2.7) 0.1 Diabetes—mild to moderate 19 (2.8) 8 (7.1) 0.1 Diabetes with end organ damage 3 (0.4) 2 (2.7) 0.1 Any tumor 19 (2.8) 8 (7.1) 0.09 -
↵* Statistically significant. COPD: chronic obstructive pulmonary disease.
-
- Table 6.
Disease activity and damage in early onset (< 50 yrs) vs late onset (≥ 50 yrs) SLE.
Early Onset Late Onset p Mean SLAM score 5.19 ± 3.86 7.07 ± 4.41 < 0.0001* Mean SLEDAI score 4.29 ± 4.31 4.39 + 4.18 0.8 Mean no. with lupus flare over last year 0.89 ± 0.98 1.04 ± 0.98 0.2 Mean disease activity (VAS) 3.43 ± 2.81 4.11 ± 2.63 0.04* Mean unusual fatigue (VAS) 4.43 ± 3.23 4.73 ± 2.60 0.4 SLAQ, self-reported, % Rash/nausea after sun exposure 33.5 48.7 0.05* Shortness of breath 40.1 59.0 0.02* Numbness/tingling 32.7 55.3 0.002* Muscle weakness 52.8 64.6 0.0008* Mean SLICC score 1.50 ± 1.94 1.80 ± 1.67 0.09 -
↵* Statistically significant. SLAM: SLE activity measure; SLEDAI: SLE Disease Activity Index; VAS: visual analog scale; SLAQ: SLE Activity Questionnaire; SLICC: Systemic Lupus International Collaborating Clinics.
-
